AAO

Karolinne M. Rocha, MD, PhD, shares advancements in vision correction and patient satisfaction at the AAO 2025 meeting.

Johnson & Johnson reaches 100,000 TECNIS ODYSSEY IOLs implanted, and presented data on in vision correction and patient satisfaction at the AAO 2025 meeting.

Data suggests that EYP-1901 can reduce the number of injections and treatment burden for patients

Dr. James Chelnis explores innovative energy-based technologies in aesthetic facial surgery, emphasizing safety, personalized treatments, and future advancements in patient care.

The professor from Wills Eye Hospital in Philadelphia, Pennsylvania, explained why it's time to retire the term "sterile" when addressing culture-negative endophthalmitis

The AAO 2025 meeting offered a platform for companies to showcase their latest technologies to advance ophthalmic patient care.

Andrew G. Lee, MD, and Drew Carey, MD, discuss the case of a patient with persistent papilledema after brain tumor resection due to superficial siderosis.

A new study reveals a promising drug reduces vision loss in Stargardt disease, showing significant safety and efficacy over 2 years.

The awards recognize outstanding contributions in 3 categories—Rising Star, Catalyst, and Visionary Leader—honoring individuals driving innovation, inclusion, and impact across ophthalmology.

Catch up on news you may have missed at the meeting in Orlando, like the effects of GLP-1 drugs on eye health and a potential sign of cardiovascular disease.

Anat Loewenstein, MD, shared recent research findings which indicate home monitoring is appropriate for atypical and complex pathologies

HELIOS Phase 1 showed consistent reductions in retinal fluid with OTX-TKI, paving the way for pivotal HELIOS-2 and HELIOS-3 trials.

Gildeuretinol has also been evaluated in atrophic age-related macular degeneration, said Philip J. Ferrone, MD

The newest research findings create "tangible benchmarks" for how earlier treatment can lead to better outcomes, said Dr. Kim.

New research reveals subretinal drusenoid deposits in Black and Hispanic AMD patients may signal higher vascular disease risk

Optogenetics shows promise in improving mobility and object recognition for patients with retinitis pigmentosa and Stargardt disease.

During the American Academy of Ophthalmology annual scientific meeting, the organization shared breaking news and updates from ongoing projects.

Joel Schuman, MD, explore the latest advancements in glaucoma laser treatments, including innovative techniques like DSLT and the benefits of selective laser trabeculoplasty

Sahar Bedrood, MD, discusses her experience with the LEOS endoscopic laser system's enhanced precision and efficiency, promising improved patient outcomes in glaucoma surgery.

Sunir J. Garg, MD, explores the nuances of endophthalmitis, distinguishing between infectious and non-infectious responses for effective patient management.

Research reveals significant vision improvements and extended treatment intervals with aflibercept 8 mg for age-related macular degeneration and diabetic edema patients.

Phase 2 STARLIGHT study participants, particularly those with the macular phenotype, experienced meaningful gains in visual acuity at 48 weeks.

Bedrood describes improved visualization of the ciliary body, efficient setup, and favorable postoperative outcomes.

The investigators noted that this report is the first about subretinal drusenoid deposits in Black and Hispanic patients with age-related macular degeneration.

Innovations in selective laser trabeculoplasty and laser cyclophotocoagulation focus on procedural efficiency, patient comfort, and evolving first-line treatment strategies.

The annual scientific meeting of the American Academy of Ophthalmology highlighted research in retina, refractive surgery, and accessible care.

John P. Berdahl, MD, discusses advanced lens options for patients with pseudoexfoliation, highlighting considerations for successful longterm outcomes.